Mitsunori Kato

This inventor holds 16 USPTO granted patents and 4 published patent applications and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Novartis Ag. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mitsunori Kato. Retrieved from https://idiyas.com/inventor/mitsunori-kato

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 4)

% Patents Active = 87.5

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 10.9

ph-index = 5

Forward Citations = 60(Granted Patents)

Location History:

Cambridge, MA (US) (2012 - 2021)
Long Island, NY (US) (2022 - 2024)

Company Filing History:

16 out of 3,978

Novartis Ag

patents

Years Active: 2012-2025

Loading Chart...

Areas of Expertise:

SHP2 Inhibitors

Soluble Guanylate Cyclase Activators

N-Heteroaryl Compounds

Indane Derivatives

Pyridazin Derivatives

Triazin Derivatives

Cyclohexen Derivatives

Furopyridine Compounds

Compositions

Chemical Compounds

Pharmaceutical Compositions

Pyrazole Derivatives

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12209098 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2025-01-28),

2. 11952386 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2024-04-09),

3. 11401259 - 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 (2022-08-02),

4. 10975080 - Compounds and compositions for inhibiting the activity of SHP2 (2021-04-13),

5. 10968235 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2021-04-06),

6. 10774065 - 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 (2020-09-15),

7. 10550102 - Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators (2020-02-04),

8. 10336774 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2019-07-02),

9. 10301278 - 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 (2019-05-28),

10. 10208018 - Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators (2019-02-19),

11. 10093646 - 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 (2018-10-09),

12. 10077276 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2018-09-18),

13. 9957254 - Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators (2018-05-01),

14. 9815813 - 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 (2017-11-14),

15. 9765067 - Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators (2017-09-19),

Title: Innovations of Mitsunori Kato

Introduction

Mitsunori Kato is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of pharmaceutical sciences. With a total of 16 patents to his name, Kato has made remarkable strides in developing innovative compounds that have the potential to impact various therapeutic areas.

Latest Patents

Among his latest patents, Kato has developed N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2. This invention relates to compounds of formula I, which are designed to provide new avenues for therapeutic intervention.

Career Highlights

Kato's career is marked by his association with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on cutting-edge research and development, contributing to the advancement of medical science.

Collaborations

Throughout his career, Kato has collaborated with notable colleagues, including Zhuoliang Chen and Jorge Garcia Fortanet. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Mitsunori Kato's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a key innovator. His work continues to pave the way for future advancements in medical treatments.

Profile summary based on public USPTO records.